Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised guidance, and more. Tue, Jan 14 202510:08 AM EST ...
Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised guidance, and more. Tue, Jan 14 202510:03 AM EST ...
Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion, demand outlook for Zepbound and Mounjaro, state of the weight...
Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported third-quarter adjusted profit and revenue that missed expectations, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, why ...